<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cabazitaxel and prednisone for metastatic, castration-resistant prostate cancer&lt;sup&gt;[1]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cabazitaxel and prednisone for metastatic, castration-resistant prostate cancer<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Cabazitaxel and prednisone for metastatic, castration-resistant prostate cancer<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="40%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"><strong>Cycle length:</strong> 21 days.</td> </tr> <tr class="divider_top"> <td class="subtitle1 divider_bottom">Drug</td> <td class="subtitle1 divider_bottom">Dose and route</td> <td class="subtitle1 divider_bottom">Administration</td> <td class="subtitle1 divider_bottom">Given on days</td> </tr> <tr> <td>Cabazitaxel</td> <td>20 mg/m<sup>2</sup> IV*</td> <td>Dilute in 250 mL NS or D5W<sup>¶</sup> and administer over one hour; special equipment and preparation techniques needed<sup>Δ</sup>.</td> <td>Day 1</td> </tr> <tr class="divider_bottom"> <td>Prednisone</td> <td>10 mg orally</td> <td>Daily.</td> <td>Days 1 to 21</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="3"> <ul> <li>MODERATE (&gt;30 to 90% frequency of emesis).</li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan="3"> <ul> <li>Severe hypersensitivity reactions may occur. Cabazitaxel is contraindicated in patients with a prior history of hypersensitivity to other drugs formulated with polysorbate 80. All patients should receive IV premedication with a corticosteroid (dexamethasone 8 mg or equivalent), an H1 receptor antagonist (diphenhydramine 25 mg or an equivalent), and an H2 receptor antagonist (famotidine 20 mg or equivalent) at least 30 minutes prior to cabazitaxel administration.</li> <li>Refer to UpToDate topics on infusion reactions to systemic chemotherapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infection prophylaxis</strong></td> <td colspan="3"> <ul> <li>Primary prophylaxis with G-CSF is not recommended for all patients (risk of febrile neutropenia 8%<sup>[1]</sup>). However, primary prophylaxis with G-CSF should be considered for all patients with high-risk clinical features: Age &gt;65 years, poor performance status, previous episodes of febrile neutropenia, extensive prior radiation, poor nutritional status, or other serious comorbidities. Bone marrow suppression is prominent with cabazitaxel, and deaths due to neutropenia are reported.</li> <li>Refer to UpToDate topics on use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan="3"> <ul> <li>Reduce cabazitaxel dose for mild to moderate hepatic impairment. Cabazitaxel is not recommended in patients with severe hepatic impairment (total bilirubin &gt;3 times ULN). Cabazitaxel should be used with caution in patients with severe renal insufficiency requiring hemodialysis.</li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents; chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents; and chemotherapy nephrotoxicity and dose modification in patients with kidney impairment, conventional cytotoxic agents.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Dose adjustment for known drug interactions</strong></td> <td colspan="3"> <ul> <li>Concurrent cabazitaxel administration with strong CYP3A4 inhibitors should be avoided due to potentially increased cabazitaxel plasma concentrations.</li> <li>If coadministration of cabazitaxel and a strong CYP3A4 inhibitor(s) is unavoidable, reduce cabazitaxel dose by 25%.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Monitoring parameters:</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>CBC with differential weekly during the first cycle and at the start of each subsequent treatment cycle.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Renal and liver function testing at least every three weeks during treatment.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor neurologic function and gastrointestinal toxicities prior to each treatment cycle.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1"><strong>Myelotoxicity</strong></td> <td colspan="3"> <ul> <li>Do not give if neutrophil count is ≤1500/microL. For prolonged grade 3 or 4 neutropenia (greater than one week) despite appropriate medication including G-CSF for febrile neutropenia, delay treatment until improvement/resolution and neutrophil count is &gt;1500/microL, then reduce dose to 20 mg/m<sup>2</sup>. Use G-CSF for secondary prophylaxis.<sup>[2]</sup> Discontinue cabazitaxel if these toxicities recur at the lower dose level.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Gastrointestinal toxicity</strong></td> <td colspan="3"> <ul> <li>For grade 3 or higher diarrhea or persisting diarrhea despite appropriate medication and fluid and electrolyte replacement, delay treatment until improvement or resolution, then reduce dose to 20 mg/m<sup>2</sup>. For persistent diarrhea despite dose reduction, discontinue cabazitaxel therapy.<sup>[2]</sup></li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Peripheral neuropathy</strong></td> <td colspan="3"> <ul> <li>For grade 2 peripheral neuropathy, delay treatment until improvement/resolution, then reduce dose to 20 mg/m<sup>2</sup>.<sup>[2]</sup> Discontinue cabazitaxel for grade 3 or grade 4 peripheral neuropathy.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="highlight_gray_text" colspan="4" style="font-size: 1.2em;"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes">IV: intravenous; NS: normal saline; D5W: 5% dextrose in water; G-CSF: granulocyte colony-stimulating factor; ULN: upper limit of normal; CYP3A4: cytochrome P450 3A4; AST: aspartate aminotransferase; ALT: alanine aminotransferase; CBC: complete blood count; PVC: polyvinyl chloride.<br/>
*A dose of 25 mg/m<sup>2</sup> can be used in select patients at the discretion of the treating health care provider.<br/>
¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br/>
Δ Do not use PVC infusion containers or polyurethane infusion sets for preparation or administration. The manufacturer requires that two dilutions are performed prior to administration. Cabazitaxel can be administered in normal saline or 5% dextrose in water at concentrations between 0.10 mg/mL and 0.26 mg/mL. Use an in-line filter of 0.22 micron nominal pore size during administration.<sup>[2]</sup></div><div class="graphic_reference">References:
<ol>
<li>de Bono JS, et al. Lancet 2010; 376:1147.</li>
<li>Cabazitaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on January 13, 2012).</li>
</ol></div><div id="graphicVersion">Graphic 82196 Version 16.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
